Merck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd.
Scientists at Swedish Karolinska Institute have identified a factor that supports growth of midbrain dopaminergic (mDA) neurons, the nerve cells that degenerate during of Parkinson’s disease.
Evotec’s immunology spin-out Topas Therapeutics has inked a multi-year R&D collaboration with pharma major Eli Lilly. The initial focus of research, which will be financed by Eli Lilly, is on identification of antigens that specifically induce a T regulatory cell response in inflammatory and auto-immune disorders.
Medivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd.
Using a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival.
Finnish Metsä Group has started its mill for bio-based products. The €1.2bn investment’s production capacity is 1.3 million tonnes of softwood pulp a year.
UK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.
German CellAct GmbH has cashed in US$250m (€212m) from Mundipharma in a licence deal for CAP7.1, a Phase II drug to treat the rare biliary tract cancer.
Germany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 study, 300 patients will be enrolled in Germany, Belgium, France and the Netherlands for proof of safety and efficacy.
Caisse de dépôt et placement du Québec (CDPQ) is set to acquire a minority stake in diagnostic electrophoresis player Sebia Group from private equity investors Astorg and Montagu.